ONCONEXT - next generation oncology diagnostics

Liquid biopsy is a non-invasive, cost effective and highly sensitive method of isolating and detecting cfDNA fragments, including circulating tumor fragments (ctDNA), from the plasma of patients diagnosed with cancer or from individuals who may have cancer. By analysing cell-free DNA isolated from a patient's blood, we can identify clinically relevant genomic alterations in ctDNA and match these alterations to targetted therapies and clinical trials.

ONCONEXT LIQUID offers a potential alternative to surgical tumour bioposy and histological assessment, eliminating many of the difficulties and concerns associated with traditional tests, as well as a means of augmenting imaging studies and other diagnostic methods.

MONITOR

ONCONEXT LIQUID Monitor test is meant for patients who have been diagnosed with cancer

Benefits provided by ONCONEXT LIQUID Monitor

ONCONEXT LIQUID Monitor provides physicians with actionable biomarker information to help guide treatment and find ongoing clinical trials for aggressive, metastatic and refractory cancer patients.

A broad base of high priority target genes are used in ONCONEXT LIQUID Monitor tests, regardless of which mutations were originally detected in the patient's tumor. This allows the detection of arising clones that may create resistance to current therapies or reveal options for additional targeted therapies.

SCAN

ONCONEXT LIQUID Scan test is meant for preventative surveillance of high risk populations.

Benefits provided by ONCONEXT LIQUID Scan

Find out more by clicking the icons below